ctDNA RAS Mutation Detection Kit

Cat Number: CTRAS-RT40

The ctDNA RAS Mutation Detection Kit is a highly sensitive plasma-based assay for detecting clinically significant KRAS and NRAS mutations in circulating tumor DNA to guide personalized cancer treatment when tumor tissue is limited or unavailable.

40 tests per kit
2-hour turnaround time
2 Reactions per sample
For research use (RUO) in the U.S
For in vitro diagnostic use (IVD) in the European Union

Request More Information

The ctDNA RAS Mutation Detection Kit is a highly sensitive, real-time PCR-based assay designed for the detection of somatic mutations in KRAS exon 2 and NRAS exons 2 and 3 from circulating tumor DNA (ctDNA) extracted from plasma. Mutations in KRAS (codons 12, 13) and NRAS (codons 12, 13, and 61) are frequently associated with resistance to anti-EGFR therapies in cancers such as metastatic colorectal cancer, highlighting the importance of RAS mutation screening for informing personalized treatment selection.

The assay utilizes allele-specific primers and fluorescent hydrolysis probes to preferentially amplify mutant DNA even in the presence of a high proportion of wild-type DNA. Two reactions detect the following mutations: KRAS G12/G13, NRAS G12/G13 (Reaction A), and NRAS Q61 (Reaction B).

This minimally invasive, plasma-based assay enables detection of clinically relevant RAS mutations when tumor tissue is insufficient or unavailable, offering an important tool for guiding therapeutic decisions in cancer management.

The list of KRAS and NRAS mutations detected by this kit is:

Gene	Exon	AA Change	Nucleotide Change	Cosmic ID	Detected by Primer
KRAS	2	G12A	c.35G>C	522	A
		G12D	c.35G>A	521
		G12R	c.34G>C	518
		G12V	c.35G>T	520
		G12C	c.34G>T	516
		G12S	c.34G>A	517
		G13D	c.38G>A	532
		G13C	c.37G>T	527
		G13R	c.37G>C	529
		G13S	c.37G>A	528
		G13A	c.38G>C	533
		G13V	c.38G>T	534
NRAS	2	G12D	c.35G>A	564	A
		G12C	c.34G>T	562
		G12S	c.34G>A	563
		G12A	c.35G>C	565
		G12R	c.34G>C	561
		G12V	c.35G>T	566
		G13R	c.37G>C	569
		G13V	c.38G>T	574
	3	Q61H (CAC)	c.183A>C	586	B
		Q61H (CAT)	c.183A>T	585
		Q61L	c.182A>T	583
		Q61K	c.181C>A	580
		Q61R	c.182A>G	584

For More Information

The ctDNA RAS Mutation Detection Kit follows a simple and easy to use process. It can be completed in 2 hours and follows a simple straightforward process.

EntroGenʼs ctDNA RAS Mutation Detection Kit requires a real-time PCR instrument capable of detecting VIC, FAM, and CY5 fluorescent probes.

This test includes reagents required for PCR amplification/detection, as well as validated reaction controls.

Columns and reagents for DNA isolation from plasma are not included. Cell-free DNA can be extracted using EntroGen’s Cell-Free DNA Isolation Kit.

	Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Andreyev, H.J., et al. (2001) Br J Cancer 85, 692-696
	K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Esteller, M., et al. (2001) J Clin Oncol 19, 299-304
	Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. Douillard, JY. et al. (2013) N Engl J Med 369, 1023-1034
	The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. Zhuang, R, Li S, Li Q, Guo X, Shen F, Sun H, et al. (2017) PLoS One 12(8): e0182562.